Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Candel Therapeutics, Inc. (CADL)
Company Research
Source: GlobeNewswire
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The 12,000,001 shares of common stock sold in the offering include 2,000,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the
Show less
Read more
Impact Snapshot
Event Time:
CADL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CADL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CADL alerts
High impacting Candel Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CADL
News
- Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock, up previously from $11.00.MarketBeat
- Candel Therapeutics Announces Pricing of Public OfferingGlobeNewswire
- Candel Therapeutics Announces $80 Million Proposed Public OfferingGlobeNewswire
- Candel Therapeutics stock up 172% after Phase III prostate cancer success [Yahoo! Finance]Yahoo! Finance
- Market movers: Stocks seeing action on Wednesday - and why [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
CADL
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SC
- 12/13/24 - Form 4
- CADL's page on the SEC website